PENBRAYA® Meningococcal Groups A, B, C, W, and Y Vaccine | Trumenba® Meningococcal Group B Vaccine

Medscape LIVE!

Information from Industry

You're Invited

Please join us for a virtual broadcast titled Risk of Invasive Meningococcal Disease in Adolescents and the Role of a Pentavalent MenABCWY Vaccine

Scan to register

Monday, June 16, 2025
12:00 - 1:00 PM ET (1 hour)

Monday, June 16, 2025
3:00 - 4:00 PM ET (1 hour)

Presented by:

Jaime E. Fergie MD, FAAP, FIDSA, FSHEA
Medical Director, Global Institute for Hispanic Health
Professor of Pediatrics, Texas A&M University
Director, Infectious Diseases Driscoll Children's Hospital
Corpus Christi, TX

Ruth M. Carrico PhD, DNP, APRN, FNP-C, CIC, FSHEA, FNAP, FAAN
Co-Owner, Carrico & Ramirez PLLC
Professor, adjunct faculty, Division of Infectious Diseases
University of Louisville School of Medicine
Louisville, KY

Speakers are paid by Pfizer.

Register for this virtual event at **https://events.medscape.com/57FC8B**

Or scan this QR code with your smart phone for quick access

On behalf of your Pfizer sales representative.

By registering, I agree to the Terms of Use and Privacy Policy and that my information may be shared with Pfizer.

IMPORTANT SAFETY INFORMATION

- Do not administer PENBRAYA or TRUMENBA to individuals with a history of severe allergic reaction (eg, anaphylaxis) to any component of PENBRAYA or TRUMENBA. Appropriate medical treatment used to manage allergic reactions must be available in the event an anaphylactic reaction occurs immediately following administration of PENBRAYA or TRUMENBA
- Syncope (fainting) may occur in association with administration of injectable vaccines, including PENBRAYA or TRUMENBA. Procedures should be in place to avoid injury from fainting
- Some individuals with altered immunocompetence may have reduced immune responses to PENBRAYA or TRUMENBA

Please read Important Safety Information, continued on next page.

IMPORTANT SAFETY INFORMATION (continued)

- Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by *N. meningitidis* groups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENBRAYA
- Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by *N. meningitidis* group B, even if they develop antibodies following vaccination with TRUMENBA
- Vaccination with PENBRAYA or TRUMENBA may not protect all vaccine recipients
- Vaccination with PENBRAYA does not substitute for vaccination with a tetanus toxoid–containing vaccine to prevent tetanus
- Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENBRAYA to individuals with a history of GBS should take into account the expected benefits and potential risks
- For PENBRAYA, the most commonly reported (≥15%) solicited adverse reactions after Dose 1 and Dose 2, respectively, were pain at the injection site (89% and 84%), fatigue (52% and 48%), headache (47% and 40%), muscle pain (26% and 23%), injection site redness (26% and 23%), injection site swelling (25% and 24%), joint pain (20% and 18%), and chills (20% and 16%)
- For TRUMENBA, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
- Data are not available on the safety and effectiveness of using TRUMENBA and other meningococcal group B vaccines interchangeably to complete the vaccination series
- The safety and effectiveness of PENBRAYA or TRUMENBA have not been established in pregnant individuals

INDICATIONS

- PENBRAYA is indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
- TRUMENBA is indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age

Please see full Prescribing Information for PENBRAYA and full Prescribing Information for TRUMENBA.

PP-PBI-USA-0446 May 2025